

Anti-PDCD1/PD-1/CD279 Antibody (Cetrelimab)

Introduction

Cetrelimab (JNJ 63723283; JNJ 3283) is a targeted PD-1 antibody. Cetrelimab is a human IgG4k monoclonal antibody. PD-1 Kd is 1.72 nM (HEK293 cells). PD-1 and PD-L1 and PD-L2 The interaction (IC50 Cetrelimab also stimulates peripheral T cells and increases cytokines (IFN- γ , IL-2, TNF- α) levels and inhibit tumor growth in vivo.

Product parameters

Alternative Names	JNJ-63723283
Target Accession	Q15116
Target	PDCD1 / PD-1 / CD279
CAS number	2050478-92-5
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

